|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
16 December 2017 |
|
Main ID: |
NCT01516229 |
|
Date of registration:
|
19/01/2012 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Special Survey for Long Term Application
|
|
Scientific title:
|
Specific Survey of Norditropin® in Achondroplasia: Survey for Long-term Application |
|
Date of first enrolment:
|
May 1, 1997 |
|
Target sample size:
|
395 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT01516229 |
|
Study type:
|
Observational |
|
Study design:
|
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
Japan
| | | | | | | |
|
Contacts
|
|
Name:
|
Global Clinical Registry (GCR, 1452) |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Novo Nordisk A/S |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Achondroplasia without epiphyseal line closure
Age minimum:
1 Year
Age maximum:
15 Years
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Genetic Disorder
|
|
Achondroplasia
|
|
Intervention(s)
|
|
Drug: somatropin
|
|
Primary Outcome(s)
|
|
Incidence of adverse drug reactions (ADRs)
|
|
Secondary Outcome(s)
|
|
Treatment evaluation using the Foundation for Growth Science's Criteria for Treatment Continuation: Definitely effective, effective, ineffective or definitely ineffective
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|